Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Harrison

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.
Radiation Oncology (London, England)|December 3, 2021
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
BMJ Open|February 12, 2024
AI assisted reader evaluation in acute CT head interpretation (AI-REACT): protocol for a multireader multicase studyHowell Fu, Alex Novak, Dennis Robert, et al.
The Journal of Rheumatology|February 2, 2022
Results From the 2020 Canadian Rheumatology Association's Workforce and Wellness SurveyStephanie C Kulhawy-Wibe, Jessica Widdifield, Jennifer J Y Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2017
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal CancerRussell D Petty, Asa Dahle-Smith, David A J Stevenson, et al.
The Lancet. Oncology|May 7, 2025
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trialAlexandra Gilbert, Richard Adams, Joanne Webster, et al.
American Journal of Public Health|March 23, 2022
Governing Global Antimicrobial Resistance: 6 Key Lessons From the Paris Climate AgreementIsaac Weldon, Susan Rogers Van Katwyk, Gian Luca Burci, et al.
The Lancet. Oncology|June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, Paul Silcocks, Trevor Cox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.
Radiation Oncology (London, England)|December 3, 2021
Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.
BMJ Open|February 12, 2024
AI assisted reader evaluation in acute CT head interpretation (AI-REACT): protocol for a multireader multicase studyHowell Fu, Alex Novak, Dennis Robert, et al.
The Journal of Rheumatology|February 2, 2022
Results From the 2020 Canadian Rheumatology Association's Workforce and Wellness SurveyStephanie C Kulhawy-Wibe, Jessica Widdifield, Jennifer J Y Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2017
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal CancerRussell D Petty, Asa Dahle-Smith, David A J Stevenson, et al.
The Lancet. Oncology|May 7, 2025
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trialAlexandra Gilbert, Richard Adams, Joanne Webster, et al.
American Journal of Public Health|March 23, 2022
Governing Global Antimicrobial Resistance: 6 Key Lessons From the Paris Climate AgreementIsaac Weldon, Susan Rogers Van Katwyk, Gian Luca Burci, et al.
The Lancet. Oncology|June 24, 2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, Paul Silcocks, Trevor Cox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority TrialTimothy Iveson, Mark P Saunders, Caroline Kelly, et al.
Pageof 24